David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$354M |
| 2 |
Wells Fargo
WFC
|
+$274M |
| 3 |
IBM
IBM
|
+$266M |
| 4 |
Qualcomm
QCOM
|
+$257M |
| 5 |
Mondelez International
MDLZ
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$356M |
| 2 |
PayPal
PYPL
|
+$290M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$261M |
| 4 |
NVIDIA
NVDA
|
+$248M |
| 5 |
AABA
Altaba Inc
AABA
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.31% |
| 2 | Healthcare | 10.66% |
| 3 | Consumer Discretionary | 10.29% |
| 4 | Communication Services | 8.78% |
| 5 | Financials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
CALL
Cognizant
CTSH
$28.4B
| $7.01M | 0.01% |
96,600
| – | – |
|
1127
Pembina Pipeline
PBA
$28B
| $7M | 0.01% |
199,395
-18,900
| -9% | -$630K |
|
1128
Toronto Dominion Bank
TD
$197B
| $7M | 0.01% |
124,230
-32,158
| -21% | -$1.69M |
|
|
DSKE
1129
DELISTED
Daseke, Inc. Common Stock
DSKE
| $6.98M | 0.01% |
534,953
-539,164
| -50% | -$6.72M |
|
1130
Copa Holdings
CPA
$6.04B
| $6.96M | 0.01% |
55,899
+42,255
| +310% | +$5.34M |
|
1131
Choice Hotels
CHH
$4.96B
| $6.95M | 0.01% |
108,770
-6,187
| -5% | -$387K |
|
1132
Verisk Analytics
VRSK
$24.5B
| $6.95M | 0.01% |
83,549
-125,549
| -60% | -$10.4M |
|
1133
Norfolk Southern
NSC
$78.9B
| $6.93M | 0.01% |
52,402
-314,229
| -86% | -$38.2M |
|
|
ISEE
1134
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.92M | 0.01% |
2,453,200
+256,619
| +12% | +$693K |
|
|
AET
1135
PUT
DELISTED
Aetna Inc
AET
| $6.9M | 0.01% |
43,400
-2,300
| -5% | -$359K |
|
1136
LivePerson
LPSN
$34.2M
| $6.87M | 0.01% |
33,784
-7,809
| -19% | -$1.5M |
|
1137
Range Resources
RRC
$9.58B
| $6.86M | 0.01% |
350,532
+232,943
| +198% | +$4.5M |
|
1138
Mid-America Apartment Communities
MAA
$15.3B
| $6.85M | 0.01% |
64,076
-3,625
| -5% | -$380K |
|
|
ZVO
1139
DELISTED
Zovio Inc. Common Stock
ZVO
| $6.84M | 0.01% |
712,433
-151,241
| -18% | -$1.57M |
|
1140
OneSpan
OSPN
$567M
| $6.84M | 0.01% |
567,262
+29,930
| +6% | +$383K |
|
|
TOWR
1141
DELISTED
Tower International, Inc.
TOWR
| $6.83M | 0.01% |
251,130
-28,092
| -10% | -$654K |
|
|
TIVO
1142
DELISTED
Tivo Inc
TIVO
| $6.82M | 0.01% |
343,526
-75,809
| -18% | -$1.42M |
|
1143
CALL
Elevance Health
ELV
$86.5B
| $6.82M | 0.01% |
35,900
-1,700
| -5% | -$324K |
|
|
HI
1144
DELISTED
Hillenbrand
HI
| $6.79M | 0.01% |
174,667
+8,677
| +5% | +$315K |
|
1145
MidCap Financial Investment
MFIC
$797M
| $6.79M | 0.01% |
370,206
+73,366
| +25% | +$1.36M |
|
|
DPLO
1146
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $6.79M | 0.01% |
327,585
-63,004
| -16% | -$1.07M |
|
1147
Nomura Holdings
NMR
$29B
| $6.77M | 0.01% |
1,214,923
+4,290
| +0.4% | +$24.6K |
|
|
TSG
1148
DELISTED
The Stars Group Inc.
TSG
| $6.75M | 0.01% |
330,300
+82,300
| +33% | +$1.48M |
|
|
MRTX
1149
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.75M | 0.01% |
577,082
+495,915
| +611% | +$2.87M |
|
|
TPH
1150
DELISTED
Tri Pointe Homes
TPH
| $6.75M | 0.01% |
488,715
+221,417
| +83% | +$2.94M |
|
Similar funds
David Shaw's Q3 2017 Portfolio in Review
As of Q3 2017, David Shaw held 3,794 positions worth $65.1B, up 7.7% from $60.5B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
David Shaw's Q3 2017 filing shows 469 new, 1,367 increased, 1,237 reduced and 370 closed positions. Its largest new stake was Baker Hughes: 3,076,914 shares worth $113M. The largest sale was Gilead Sciences, an estimated $356M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- David Shaw's largest Q3 2017 buy was Baker Hughes: 3,076,914 shares worth $113M.
- David Shaw added most to Comcast in Q3 2017, an estimated $354M increase.
- David Shaw's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $356M.
- David Shaw fully exited Mobileye N.V. in Q3 2017, selling an estimated $72.4M.
- David Shaw's ten largest holdings make up 9.6% of its $65.1B portfolio in Q3 2017.
- David Shaw opened 469 new positions and closed 370 in Q3 2017.
- David Shaw's portfolio value rose 7.7% quarter-over-quarter to $65.1B.
Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.